Jade Biosciences
JBIO
17 hedge funds and large institutions have $454M invested in Jade Biosciences in 2021 Q2 according to their latest regulatory filings, with 17 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$189M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$85.8M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$46.4M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$36.9M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$32.6M |
Top Sellers
JBIO Hedge Fund Activity: Q2 2021 in Review
17 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Jade Biosciences (JBIO) for Q2 2021, worth a combined $454M.
Buyers outnumbered sellers: 17 funds opened new JBIO positions and 0 closed out — a net gain of 17 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $189M.
- 17 institutional investors held Jade Biosciences (JBIO) as of Q2 2021, up from 0 in Q1 2021.
- Funds reported $454M of Jade Biosciences stock for Q2 2021.
- 17 funds opened new Jade Biosciences positions in Q2 2021 and 0 closed out, a net change of +17 holders.
- The largest Jade Biosciences buyer in Q2 2021 was RA Capital Management, an estimated $189M added.
Based on aggregated 13F filings for Q2 2021.